Why technology standards are critical for Quantum-Safe Security

Safeguard Insights

December 30, 2011

2011 in Review: A Year of Innovation, Record Net Cash and The Cultivation of Enterprise 3.0

As 2011 comes to a close, it offers us an opportunity to look back at the major milestones and key events of the year. While…

Posted by John E. Shave III

December 22, 2011

Supporting our Partner Companies with Veteran Advice

At Safeguard Scientifics, we offer our partner companies quality resources to promote their growth and help them recruit strong management teams for their future. We…

Posted by Peter J. Boni

December 2, 2011

Week in Review: Why Startups Falter, Safeguard’s Strong Track Record, and Swap.com Defines an Industry

Contrary to popular belief, a startup’s success does not solely hinge on the idea, but the leadership and talent that drive the company forward. For…

Posted by John E. Shave III

December 1, 2011

Defining Safeguard Scientifics: Not Venture Capital. Not Private Equity. And More than Just Capital.

Here at Safeguard Scientifics, we provide capital to growth-stage companies in both the life sciences and technology. It’s important to note, however, that Safeguard provides…

Posted by John E. Shave III

November 23, 2011

A Focus on Life Sciences

Safeguard Scientifics has a unique and consistent approach to putting capital to work in the life sciences sector. We target capital efficient diagnostic companies that…

Posted by James A. Datin

November 21, 2011

The Power of emPower!

PixelOptics’ emPower! eyewear is the world’s first and only electronic focusing eyeglasses—focusing faster than the blink of an eye. The technology is embedded inside the lenses and…

Posted by James A. Datin

November 18, 2011

Week in Review: Convergence between Life Sciences and Technology and A Look at New Partner Company Medivo

The convergence between life sciences and technology cannot be ignored. That’s why at Safeguard Scientifics, we consolidated of our life sciences and technology deal teams.…

Posted by John E. Shave III

November 15, 2011

Opportunity in the Migraine Market for NuPathe

Ninety percent of migraine sufferers experience nausea, while 60 percent experience vomiting because of their migraine. As a result, today’s most common migraine treatments that…

Posted by James A. Datin

November 11, 2011

Anatomy of a Deal: Advanced BioHealing

Last week our own Gary J. Kurtzman, MD, Senior Vice President and Managing Director in the Safeguard Life Sciences Group, participated on a panel at…

Posted by James A. Datin

Content